Pet Health Refills Face More Retail Competition as Demand Weakens

|11 min read
Female veterinarian standing in clinic waiting room with female client and her large dog, discussing results of an exam.

Theme this week

Pet health refills and repeat purchases face more retail competition this week. Amazon and Elanco are expanding retail access, Zoetis reported weaker U.S. companion animal demand, and Cencora’s planned MWI–Covetrus combination may change distributor orders, pharmacy support, account contacts, and platform access. Review outside refill requests, category level prices, pharmacy rules, and distributor reliance now.

New to PULSE? Start here to get more out of PULSE intelligence briefs.

Executive takeaways

  1. Review Tessie for formulary and client education this week. FDA approved the prescription-only oral solution for noise aversion and separation anxiety in dogs, creating a new option before fireworks and storm season. 1
  2. Track where parasite-prevention refills are filled each week. Elanco reported Credelio Quattro reached more than 40% of U.S. clinics and added Costco and Dollar General as U.S. parasiticide customers. 2
  3. Review premium companion animal drug pricing this month. Zoetis reported an 11% decline in U.S. companion animal product sales and cited weaker demand, competition, price sensitivity, generic competition, and lower Librela sales. 3
  4. Count requests to refill prescriptions outside the clinic during major retail promotions. Amazon expanded Pet Days to 5 days and connects pet health products, Subscribe and Save, and prescription medications through Vetsource. 4
  5. Map distributor and pharmacy contact points within 30 days. Cencora’s planned MWI–Covetrus combination may change account contacts, service levels, platform access, and who handles support problems. 5

Signals

1. FDA approves Tessie for canine noise aversion and separation anxiety

OBSERVED

The U.S. Food and Drug Administration (FDA) approved Tessie, tasipimidine oral solution, on May 6, 2026, for treatment of noise aversion and separation anxiety in dogs. FDA described Tessie as the first FDA-approved treatment for both conditions and said it is a prescription product. 1

VIEWPOINT

Tessie creates a new prescription option for common canine behavior complaints. Operational work will center on formulary review, staff education, client questions, ordering and stocking, and seasonal communication. Clinics should prepare before summer noise events.

CONFIDENCE

High — supported by FDA’s approval notice; launch timing, stocking, and practice adoption remain the main uncertainties.

ACTIONS

Independent veterinary practices

  • Add Tessie to formulary review this week.
  • Prepare client facing educational copy before July noise events.

Corporate veterinary groups and clinic consolidators

  • Review behavior medication protocols within 30 days.
  • Plan network training this month.

Distributors, e-retail and home delivery providers

  • Confirm ordering, stocking, dispensing, and substitution steps this month.
  • Track behavior product inquiries weekly.

Manufacturers and commercial operators

  • Track competitor education activity this month.
  • Prepare compliant account materials now.

↑ Back to top

2. Elanco expands parasiticide access through clinics and retail

OBSERVED

Elanco reported Q1 2026 revenue of $1.371 billion and Pet Health revenue of $710 million on May 6, 2026. Elanco raised 2026 revenue guidance to $5.010 billion to $5.085 billion, said Credelio Quattro penetrated more than 40% of the U.S. clinic base, and added Costco and Dollar General as U.S. parasiticide retail customers. 2

VIEWPOINT

Elanco is increasing clinic uptake of Credelio Quattro while adding retail places where clients can buy parasiticides. That combination could reduce how many refills stay with the clinic after the first fill. Clinics should track whether repeat parasite prevention purchases stay with the clinic, turn into requests for written prescriptions, or move to retail and autoship channels.

CONFIDENCE

High — supported by Elanco’s investor release; clinic level refill impact remains the main uncertainty.

ACTIONS

Independent veterinary practices

  • Track where parasiticide first fills and refills are completed this week.
  • Update staff script wording for refill requests within 30 days.

Corporate veterinary groups and clinic consolidators

  • Compare parasiticide product mix and share by region this month.
  • Review which parasiticides each site carries or recommends within 30 days.

Distributors, e-retail and home delivery providers

  • Track repeat prevention orders weekly by clinic account.
  • Review inventory tied to products or channels at risk this month.

Manufacturers and commercial operators

  • Summarize weekly retail price checks for internal review
  • Brief field teams this month on retail prices and the risk of refills moving away from clinics.

↑ Back to top

3. Zoetis reports weaker U.S. companion animal demand

OBSERVED

Zoetis reported Q1 2026 U.S. segment revenue of $1.1 billion, down 8% from Q1 2025. Zoetis said U.S. companion animal product sales decreased 11%, citing weaker demand, more competition, price sensitivity, generic competition affecting Convenia and Cerenia, and lower Librela sales. 3

VIEWPOINT

This Zoetis report is the strongest signal in this edition to indicate demand for higher-cost companion animal products is weakening. The issue spans weaker demand, stronger competition, client price sensitivity, and sales moving to generic alternatives. Operators should use this as a reason to review categories. The most affected areas are dermatology, parasiticides, OA pain products, higher-cost therapeutics, and price conversations in clinics.

CONFIDENCE

High — supported by Zoetis’s investor release; the mix of visit, price, competition, and product effects remains the main uncertainty.

ACTIONS

Independent veterinary practices

  • Review prices for top companion animal medicines this month.
  • Track requests for written prescriptions weekly.

Corporate veterinary groups and clinic consolidators

  • Estimate margin risk by category this month.
  • Standardize how generic substitutions are recorded within 30 days.

Distributors, e-retail and home delivery providers

  • Track dermatology and OA demand weekly.
  • Review stock levels this month.

Manufacturers and commercial operators

  • Review net-price risk by Stock Keeping Unit (SKU) and customer segment this month.
  • Update field team guidance on price questions, objections, and generic substitution within 30 days.

↑ Back to top

4. Amazon adds pet health refills to longer Pet Days event

OBSERVED

Amazon said "Pet Days" runs May 11–15, 2026, and expanded to 5 full days for the first time. The company said customers can shop pet health products, use Subscribe and Save for pet health products, and buy pet prescription medications on Amazon.com through Vetsource. 4

VIEWPOINT

Amazon is turning pet health into a longer retail promotion that puts autoship, prescription medications, and health products together. That may change where clients refill prescriptions when they compare price, convenience, delivery, and checkout in one place. Clinics should focus on where refill requests go and where they are filled. Practices and groups should watch requests to fill prescriptions outside the clinic, staff time spent approving outside refills, and prevention purchases moving outside the clinic during major retail promotions.

CONFIDENCE

High — supported by Amazon’s “Pet Days” page; actual prescription and health product conversion during the event remains the main uncertainty.

ACTIONS

Independent veterinary practices

  • Count requests to fill prescriptions outside the clinic this week.
  • Refresh refill wording before seasonal reminder messages.

Corporate veterinary groups and clinic consolidators

  • Measure prevention autoship orders filled outside clinic channels by region this month.
  • Review policy for outside pharmacy requests within 30 days.

Distributors, e-retail and home delivery providers

  • Track delays in approving outside prescription requests daily during retail promotions.
  • Review delivery and order-status messages this month.

Manufacturers and commercial operators

  • Track marketplace prices during Pet Days.
  • Assess which products face retail promotion risk this month.

↑ Back to top

5. Cencora moves MWI–Covetrus combination forward

OBSERVED

Cencora reported fiscal Q2 2026 results on May 6, 2026. Cencora said it entered a definitive agreement with Covetrus under which MWI Animal Health and Covetrus will merge into a combined animal health platform. 2026 guidance treats MWI as a business expected to be sold or separated. 5

VIEWPOINT

The planned platform would combine distribution, practice technology, pharmacy, and practice services. The commercial issue is how customer terms, supplier account coverage, platform access, service levels and support handoffs may change. Operators should record current contacts, terms, systems, service performance, and open support issues before integration activity begins.

CONFIDENCE

High — supported by Cencora’s investor release; post transaction execution and customer migration remain the main uncertainties.

ACTIONS

Independent veterinary practices

  • List current distributor contacts this week.
  • Track order and service delays weekly.

Corporate veterinary groups and clinic consolidators

  • Map clinics that rely on MWI within 30 days.
  • Assign weekly reporting for purchasing problems this month.

Distributors, e-retail and home delivery providers

  • Review plans for moving customers between systems or contacts this month.
  • Track service complaints weekly.

Manufacturers and commercial operators

  • List contracts and accounts that depend on specific distributors this month.
  • Prepare questions for supplier and distributor reviews now.

↑ Back to top

Early watch item

1. Travv funding points to AI tools moving deeper into diagnostic workflow

OBSERVED

The Journal Record reported on May 7, 2026, that Travv announced a $1.6 million seed funding round to support development of its AI-native veterinary diagnostic platform. The round was led by Digitalis Ventures, with AniVC joining. Travv said the investment will support product expansion, adding hospitals to the platform, sales growth, and integrations with other systems. 6

Travv’s site describes cloud-based veterinary diagnostics, AI-supported tests, data labeling for clinical AI, and a platform focused on radiology and pathology. 7

SPECULATIVE ASSESSMENT

This may be an early sign that veterinary diagnostic AI is moving from image interpretation toward tools that support ordering, reporting, lab data exchange, and follow up inside hospitals. The key question is whether Travv becomes part of daily diagnostic work inside hospitals, including ordering, imaging, reporting, and lab data exchange. Current evidence shows funding plus company positioning. Hospital adoption, system integration, faster results, and staff-time savings still need proof.

CONFIDENCE

Moderate — supported by a dated secondary report and Travv’s own product materials; hospital uptake and integration depth remain open.

WHAT WOULD CONFIRM THIS

  • Named hospital pilots with ordering, reporting, turnaround time, or staff-time metrics this quarter.
  • Integration announcements with imaging, lab, or practice-management systems.
  • Published results on turnaround time, report quality, or how cases move through the workflow.
  • Expansion from radiology into pathology, lab data, or other diagnostic areas.

WHAT WOULD RULE THIS OUT

  • Limited pilot activity after the seed round.
  • Few named integrations or limited data sharing between systems by the next product update.
  • Hospital feedback showing extra manual steps or slower case handling.
  • Use limited to radiology, with few links to ordering, reporting, or lab data.

HOW TO PREPARE NOW

Independent veterinary practices

  • List where diagnostic ordering, image transfer, reporting, billing, and follow up move between staff or systems this month.
  • Track radiology turnaround time weekly.

Corporate veterinary groups and clinic consolidators

  • Define AI diagnostics pilot metrics for turnaround time, report quality, case handling, and staff time within 30 days.
  • Review imaging, practice-management system, reporting, lab data, and billing integration requirements this month.

Distributors, e-retail and home delivery providers

  • Map diagnostic service partners this month.
  • Track demand for cloud-based diagnostic services this quarter.

Manufacturers and commercial operators

  • Track funding for diagnostic platforms during category review.
  • Review AI diagnostics claims for accuracy, clinical validation, staff time savings, and turnaround time language this quarter.

↑ Back to top

Methodology and governance

This PULSE Edition covers developments posted or acted on from May 6 to May 13, 2026, using U.S. Eastern Time.

Observed statements are anchored to public sources and attributed subscriber reports cited below. Viewpoints are PETMETRIX assessments that interpret commercial implications for operators. Early watch items are early hypotheses. They are not yet strong enough for a full Signal, and they include what would confirm or rule out the pattern.

PETMETRIX PULSE commercial intelligence is provided for informational use and to support lawful, independent business decisions. It is not legal, clinical, reimbursement, accounting, or financial advice. Route legal, clinical, reimbursement, accounting, and financial decisions to qualified advisers. Respect for the veterinary-client-patient relationship is mandatory.

Terms of Service | Privacy Policy | Methodology and Data Disclaimer

Glossary

Autoship: Automatic recurring delivery of pet products or medicines on a set schedule.

Canine noise aversion: Fear or anxiety in a dog triggered by sounds such as fireworks, thunder, or loud events.

Confidence: PETMETRIX rating of the strength and consistency of a signal. It is expressed as High, Moderate, or Low and does not mean certainty.

FDA conditional approval: FDA animal-drug status that can allow marketing for a specific use while the sponsor collects the effectiveness data needed for full approval.

Formulary review: A clinic or group review of whether to add, stock, recommend, or prescribe a product.

Mesenchymal stromal cell (MSC) therapy: A cell-based treatment that uses mesenchymal stromal cells.

Parasiticide: A product used to kill, prevent, or control parasites such as fleas, ticks, heartworms, or intestinal worms.

Separation anxiety: Anxiety or distress a dog shows when separated from the owner or usual caregiver.

Speculative assessment: A forward-looking hypothesis based on early indicators, with criteria that would confirm or rule out the pattern.

Viewpoint: PETMETRIX interpretation of observed facts through a commercial lens.

References

  1. U.S. Food and Drug Administration. “FDA Approves First Drug to Treat Noise Aversion and Separation Anxiety in Dogs.” May 6, 2026. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-treat-noise-aversion-and-separation-anxiety-dogs
  2. Elanco Animal Health. “Elanco Animal Health Reports First Quarter 2026 Results.” May 6, 2026. https://investor.elanco.com/press-releases/press-releases-details/2026/Elanco-Animal-Health-Reports-First-Quarter-2026-Results/default.aspx
  3. Zoetis. “Zoetis Announces First Quarter 2026 Results.” May 7, 2026. https://investor.zoetis.com/news/news-details/2026/Zoetis-Announces-First-Quarter-2026-Results/default.aspx
  4. Amazon. “What is Amazon Pet Days? Shop top deals & discounts May 11-15.” Accessed May 13, 2026. https://www.aboutamazon.com/news/retail/what-is-amazon-pet-day
  5. Cencora. “Cencora Reports Fiscal 2026 Second Quarter Results.” May 6, 2026. https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-Second-Quarter-Results/default.aspx
  6. The Journal Record. “Travv raises $1.6M for AI veterinary diagnostics platform.” May 7, 2026. https://journalrecord.com/2026/05/07/travv-secures-seed-funding-ai-veterinary-diagnostics/
  7. Travv. “The Future of Intelligent Veterinary Diagnostics.” Accessed May 13, 2026. https://travv.com/
  8. Gallant. “Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility.” May 6, 2026. https://www.gallant.com/news/gallant-advances-canine-osteoarthritis-iv-delivered-stem-cell-therapy-with-promising-pilot-data-and-expanded-fda-conditional-approval-pathway-eligibility/
↑ Back to top